Articles from ASLAN PHARMACEUTICALS LIMITED

SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole operating subsidiary, ASLAN Pharmaceuticals Pte Ltd (“ASLAN SG”), has filed for voluntary liquidation. The decision follows a comprehensive review by the Board of the Company of ASLAN SG’s financial position and strategic alternatives. Effective immediately, all employees of ASLAN SG and fellow subsidiary ASLAN Pharmaceuticals (USA) Inc. have been terminated.

SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company’s non-compliance with the $1.00 bid price and $2.5 million stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff had determined to delist the Company’s securities from Nasdaq. Upon consideration by the Company’s board of directors, the Company has determined not to request a hearing before the Nasdaq Hearings Panel.

SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares.

SAN MATEO, Calif. and SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the late-breaking poster presentation of translational data from head-to-head studies of eblasakimab and dupilumab in human healthy and COPD-derived lung tissue models at the American Thoracic Society (ATS) International Conference 2024 in San Diego, California.

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

SAN MATEO, Calif. and SINGAPORE, May 07, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will today host a virtual KOL event, during which Company management will present new data from the interim analysis of the Phase 2 TREK-DX study of eblasakimab in dupilumab-experienced atopic dermatitis (AD) patients. The KOL event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market”, will begin at 8:00 am ET and participants may register here.

SAN MATEO, Calif. and SINGAPORE, May 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo Co., Ltd. (Zenyaku), to establish a framework for a succession of research projects to explore the differentiation of eblasakimab’s mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.

SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host a virtual Key Opinion Leader (KOL) Event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market”, to be held on Tuesday, May 7, 2024 from 8:00 AM ET to 9:00 AM ET.

SAN MATEO, Calif. and SINGAPORE, April 22, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive interim results from the Phase 2 study of eblasakimab in moderate-to-severe atopic dermatitis (AD) adult patients previously treated with dupilumab, TREK-DX. The primary endpoint, which is the percent change in Eczema Area Severity Index (EASI) score from baseline to week 16, was statistically significant when compared to placebo (p=0.0059), even though the interim analysis was not powered for statistical significance due to the sample size. 73.3% (11/15) of eblasakimab-treated patients achieved a reduction in EASI score of at least 75% from baseline (EASI-75) compared to 14.3% (1/7) on placebo (p=0.0431).

SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Letter”) on April 18, 2024 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million (the “Stockholders’ Equity Requirement”).

SAN MATEO, Calif. and SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent corporate activities.

SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders, to be held virtually on Thursday, March 28, 2024. ASLAN management will also be available for one-on-one meetings with investors on the day of the conference. Please register for the event via this link or contact your representative at H.C. Wainright to schedule a meeting.   

SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares (“ADSs”), each ADS representing twenty-five (25) ordinary shares, at an offering price of $1.00 per ADS in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,000,000 ADSs. The warrants have an exercise price of $1.00 per ADS, will be exercisable upon issuance, and will expire five years following issuance. The closing of the offering is expected to occur on or about March 14, 2024, subject to the satisfaction of customary closing conditions.

SAN MATEO, Calif. and SINGAPORE, March 11, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has begun to enroll patients in the US under an updated protocol in the ongoing TREK-DX trial, studying eblasakimab in dupilumab-experienced patients with moderate-to-severe atopic dermatitis (AD).

SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced new positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease (COPD) that provides further support for the potential of eblasakimab as a biologic therapy for COPD. In addition, the Company announced the appointment of respiratory experts Dr Ramaswamy Krishnan, MS MPhil PhD, Associate Professor in Emergency Medicine, Harvard Medical School, and Dr Reynold Panettieri Jr, MD, Vice Chancellor, Translational Medicine and Science, Rutgers University to ASLAN’s Scientific Advisory Board as it evaluates the potential use of eblasakimab as a therapy to treat COPD in addition to atopic dermatitis (AD).

SAN MATEO, Calif. and SINGAPORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced it has received a favorable patentability opinion from the European Patent Office (EPO) acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043.

SAN MATEO, Calif. and SINGAPORE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on January 5, 2024, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of the Company's listed securities for the 30 consecutive business days ended January 4, 2024, the Company has not met the minimum bid price requirement set forth in Listing Rule 5550(a)(2) during that period. The Notice is only a notification of deficiency and has no immediate effect on the listing of the Company’s American Depositary Shares (“ADS”). The Company’s ADSs will continue to trade on the Nasdaq Capital Market at this time. The Company’s receipt of the Notice does not impact the Company’s business, operations or reporting requirements with the Securities and Exchange Commission.

SAN MATEO, Calif. and SINGAPORE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its participation in upcoming conferences for January 2024. Listed below are meetings that management will be attending around the week of the J.P. Morgan 42nd Annual Healthcare Conference.

SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.

SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside discussion at the Piper Sandler Healthcare Conference. The conference will be held from November 28 to 30, 2023, in-person at the Lotte New York Palace Hotel, in New York.

SAN MATEO, Calif. and SINGAPORE, Nov. 03, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced new data was presented at the Dermatology Drug Development Summit (DDDS) that took place in Boston, MA, from October 31 to November 2, 2023. The datasets presented strengthen evidence for eblasakimab’s differentiated mechanism of action in atopic dermatitis (AD), and, for the first time, show application in a new indication, chronic obstructive pulmonary disease (COPD), which can be driven by Type 2 inflammation.

SAN MATEO, Calif. and SINGAPORE, Oct. 27, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent corporate activities.

SAN MATEO, Calif. and SINGAPORE, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), (“ASLAN”), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that it will co-host a virtual investor event today with a leading Clinical Research Organization (CRO), entitled “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab’s Introduction”, at 11:00am – 12:00pm ET. Registration for the webcast is accessible online here.

SAN MATEO, Calif. and SINGAPORE, Oct. 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will co-host a panel discussion with a leading Clinical Research Organization (CRO), “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab’s Introduction”, that will feature Key Opinion Leaders (KOLs) Jonathan Silverberg, MD, PhD, MPH (The George Washington University School of Medicine and Health Sciences), and April W. Armstrong, MD, MPH (UCLA Health).  

SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that four abstracts on eblasakimab and farudodstat have been accepted for e-poster and oral presentations at the 32nd European Academy of Dermatology and Venereology (EADV), taking place from October 11 to 14, 2023, in Berlin, Germany, at the Messe Congress Centre.

SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give an in-person company presentation at the H.C. Wainwright 25th Annual Global Investment Conference, to be held both virtually and in-person at the Lotte New York Palace Hotel in New York City, from September 11 to 13, 2023.

SAN MATEO, Calif. and SINGAPORE, Aug. 11, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate activities.

SAN MATEO, Calif. and SINGAPORE, July 06, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive topline data from its Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD), the TREK-AD (TRials with EblasaKimab in Atopic Dermatitis) study. Eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo with statistical significance in three dosing arms: 600mg dosed once every 4 weeks (600mg Q4W), which was numerically the best performing arm, 400mg dosed once every 2 weeks (400mg Q2W) and 300mg dosed once every 2 weeks (300mg Q2W).

SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the topline data from the global Phase 2b TREK-AD trial of eblasakimab in patients with moderate-to-severe atopic dermatitis on July 6, 2023, at 8:30 am ET. Management will host a question and answer session following the formal presentation.

SAN MATEO, Calif. and SINGAPORE, June 23, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the publication of data from the Phase 1a single ascending dose study of eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, in Clinical Immunology, a bimonthly peer-reviewed journal, supporting eblasakimab’s potential as a novel, differentiated treatment for atopic dermatitis (AD).

SAN MATEO, Calif. and SINGAPORE and TOKYO, June 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and a leading Japanese pharmaceutical company Zenyaku Kogyo Co., Ltd. (“Zenyaku”), a subsidiary of privately held Zenyaku Holdings Co., Ltd. (“Zenyaku Holdings”), today announced a strategic licensing agreement granting Zenyaku exclusive rights to develop and commercialize eblasakimab in atopic dermatitis (AD) and all other indications in Japan.

SAN MATEO, Calif. and SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will present a company update at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY, from June 7 to 9, 2023. Presentation details are below. ASLAN management will also be available for one-on-one meetings on the day of the presentation.

SAN MATEO, Calif. and SINGAPORE, May 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has dosed the first patient in a Phase 2a proof-of-concept study of farudodstat, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, in adult patients with severe alopecia areata (AA), an autoimmune condition causing hair loss. The study, called “FAST-AA” (FArudodstat STudy in Alopecia Areata), will investigate farudodstat’s efficacy and safety in patients with at least 50% scalp hair loss.

SAN MATEO, Calif. and SINGAPORE, May 15, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of new eblasakimab and farudodstat data in late-breaker oral and poster presentations respectively, at the 1st International Societies for Investigative Dermatology (ISID) meeting, which took place from May 10 to 13, 2023, in Tokyo, Japan.

SAN MATEO, Calif. and SINGAPORE, April 28, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate activities.

SAN MATEO, Calif. and SINGAPORE, April 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the acceptance of two late-breaker abstracts - one on eblasakimab and one on farudodstat – for presentation at the 1st International Societies for Investigative Dermatology (ISID) Meeting, which will take place from May 10 to 13, 2023, in Tokyo, Japan. Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.

SAN MATEO, Calif. and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.

SAN MATEO, Calif. and SINGAPORE, March 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.

SAN MATEO, Calif. and SINGAPORE, March 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will be available for one-on-one meetings and participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023. Details for the fireside chat are as follows:

SAN MATEO, Calif. and SINGAPORE, March 14, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that two abstracts on eblasakimab have been accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting, taking place from May 10 to 13, 2023, in Tokyo, Japan. Posters being presented at the meeting explore eblasakimab’s clinical efficacy in difficult to treat areas, such as the head and neck, and its potential for alleviating the underlying itch and hypersensitized sensory nerve fibers through multiple molecular pathways in atopic dermatitis.

SAN MATEO, Calif. and SINGAPORE, March 10, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing five (5) ordinary shares to one (1) ADS representing twenty-five (25) ordinary shares.

SAN MATEO, Calif. and SINGAPORE, March 08, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will be hosting a virtual research and development day on Thursday, March 16, 2023, from 10:00 am – 11:30 am ET.

SAN MATEO, Calif. and SINGAPORE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it is advancing its clinical program to investigate farudodstat, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, in a Phase 2 proof-of-concept trial as a potential first-in-class treatment for alopecia areata (AA).

SAN MATEO, Calif. and SINGAPORE, Feb. 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a definitive purchase agreement (“Purchase Agreement”) to raise gross proceeds of approximately $20 million resulting from the sale of its ordinary shares (or pre-funded warrants) and accompanying purchase warrants, at a purchase price of $0.178 per ordinary share (or the equivalent of $0.89 per American Depositary Share (“ADS”)) to BVF Partners L.P., K2 HealthVentures and certain existing investors (the “Investors”). In addition, ASLAN will have the potential to receive up to an additional $80 million if all purchase warrants being issued in connection with the Purchase Agreement are fully exercised.

SAN MATEO, Calif. and SINGAPORE, Feb. 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has enrolled the final patient in TREK-AD, a Phase 2b dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis (AD). ASLAN expects to report topline data from this study in early July 2023.

SAN MATEO, Calif. and SINGAPORE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and Thermo Fisher Scientific Inc (NYSE: TMO), the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD).

SAN MATEO, Calif. and SINGAPORE, Dec. 16, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the Company’s participation in upcoming conferences for January 2023. Listed below are meetings that management will be attending around the week of the J.P. Morgan 41st Annual Healthcare Conference.

SAN MATEO, Calif. and SINGAPORE, Dec. 15, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has screened the first patient in its TREK-DX study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD) who have previously been treated with dupilumab. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile.

SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET. The conference will be held from November 29 to December 1, 2022, in-person at the Lotte New York Palace Hotel, New York, NY.

SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London.

SAN MATEO, Calif. and SINGAPORE, Oct. 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate activities.

MENLO PARK, Calif. and SINGAPORE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of new translational eblasakimab data at the 51st Annual European Society for Dermatological Research (ESDR) Meeting. Two posters are being presented as e-posters throughout the duration of the congress from September 28 to October 1, 2022, in Amsterdam, Netherlands.